Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

Journal of Clinical Oncology

Volumn 18, Issue 9, 2000, Pages 1921-1927

  Kaufman, Donald ^a   Raghavan, Derek ^a   Carducci, Michael ^a   Levine, Ellis Glenn ^a   Murphy, Barbara ^a   Aisner, Joseph ^a   Kuzel, Timothy ^a   Nicol, Steven ^a   Oh, William ^a   Stadler, Walter ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HEMATURIA; HUMAN; MALE; METASTASIS; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA; VOMITING;

EID: 17444437833     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.9.1921     Document Type: Article

References (22)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1999. CA Cancer J Clin 49:8-31, 1999
2. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxyrubicin and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 64:2448-2458, 1989
3. Loehrer PJ, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, doxorubicin in patients with metastatic urothelial carcinoma. J Clin Oncol 10:1066-1073, 1992
4. Tannock I, Gospodarowicz M, Connolly J, et al. M-VAC (methotrexate, vinblastine, doxyrubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 142:289-292, 1989
5. Dimopulos MA, Finn L, Logothetis CJ, et al: Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cisplatin based chemotherapy. J Urol 151:598-601, 1994
6. Roth BJ: Chemotherapy for advanced bladder cancer. Semin Oncol 23:633-644, 1996
7. Raghavan D, Huben R: Management of bladder cancer. Curr Probl Cancer 19:1-64, 1995
8. Saxman SB, Propert KJ, Einhorn LH, et al: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 15: 2564-2569, 1997
9. Pollera CF, Ceribelli A, Crecco M, et al: Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 5:182-184, 1994
10. Lorusso V, Pollera CF, Antimi M, et al: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer 34:1208-1212, 1998
11. Stadler WM, Kuzel TM, Roth B, et al: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394-3398, 1997
12. Moore MJ, Tannock IF, Ernst DS, et al: Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15:3441-3445, 1997
13. Noble S, Goa KL: Gemcitabine: A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 54:447-472, 1997
14. Bergman AM, Ruiz van Haperen VW, Veerman G, et al: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2:521-530, 1996
15. Braakhuis BJ, Ruiz van Haperen VW, Welters MJ, et al: Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 31:2335-2340, 1995
16. Steward WP: Combination studies with gemcitabine in the treatment of non-small-cell lung cancer. Br J Cancer 78:15-19, 1998 (suppl 3)
17. Sandler A, Nemunatits J, Dehman C, et al: Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advance nonsmall cell lung cancer. Proc Am Soc Clin Oncol 17:454a, 1998 (abstr 1747)
18. Logothetis CJ, Dexeus FH, Finn L, et al: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055, 1990
19. Santoro A, Santoro M, Maiorino L, et al: Phase II trial of gemcitabine plus carboplatin for urothelial transitional cell carcinoma in advanced or metastatic stage. Ann Oncol 9:647, 1998 (suppl 2) (abstr)
20. Vaishampayan U, Smith D, Redman B, et al: Phase II evaluation of carboplatin, paclitaxel and gemcitabine in advanced urothelial carcinoma. Proc Am Soc Clin Oncol 18:333a, 1998 (abstr 1282)
21. Meluch AA, Greco FA, Burris HA III, et al: Gemcitabine and paclitaxel in combination for advanced transitional cell carcinoma (TCC) of the urothelial tract: A trial of the Minnie Pearl Research Network. Proc Am Soc Clin Oncol 18:347a, 1998 (abstr 1338)
22. Moore MJ, Winquist E, Murry N, et al: Gemcitabine plus cisplatin: An active regimen in advanced urothelial cancer. A phase II trial of the NCIC Clinical Trials Group. J Clin Oncol 17:2876-2881, 1999